SummaryObjectiveTo report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management.Case ReportsThe patient in the first case developed grade 4 toxicity and had a partial response after the fourth dose of intravenous methylene blue was administered. Full recovery occurred 4 days after the development of IIE. The patient in the second case, who had grade 3 toxicity, had completely recovered 32 hours after the first dose of thiamine.ConclusionCareful evaluation of patients with recurrent gynecologic cancers and vigilance during infusion of chemotherapeutic regimens are important in reducing the risk and timely management of IIE. Both methylene blue and thiamine appear to be effect...
Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are character...
Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are character...
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aim...
SummaryObjectiveTo report two cases of recurrent uterine sarcoma that developed ifosfamide-induced e...
Ifosfamide, an alkylating agent used in cancer treatments, can cause neurotoxicity. The clinical pre...
Introduction Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pedia...
Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe ...
Background/PurposeIfosfamide, a widely used chemotherapeutic agent, has been frequently associated w...
Ifosfamide associated central nervous system toxicity has been reported in 5% to 30%of patients trea...
Background: Dose intensive chemotherapy has not been tested prospectively for the treatment of gynec...
BACKGROUND: Dose intensive chemotherapy has not been tested prospectively for the treatment of gynec...
Background: The aim of this study was to assess the pharmacology, toxicity and activity of high-dose...
BACKGROUND: The aim of this study was to assess the pharmacology, toxicity and activity of high-dose...
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopat...
Ifosfamide is an alkylating antineoplastic prodrug used to treat many solid tumors. The metabolism o...
Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are character...
Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are character...
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aim...
SummaryObjectiveTo report two cases of recurrent uterine sarcoma that developed ifosfamide-induced e...
Ifosfamide, an alkylating agent used in cancer treatments, can cause neurotoxicity. The clinical pre...
Introduction Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pedia...
Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe ...
Background/PurposeIfosfamide, a widely used chemotherapeutic agent, has been frequently associated w...
Ifosfamide associated central nervous system toxicity has been reported in 5% to 30%of patients trea...
Background: Dose intensive chemotherapy has not been tested prospectively for the treatment of gynec...
BACKGROUND: Dose intensive chemotherapy has not been tested prospectively for the treatment of gynec...
Background: The aim of this study was to assess the pharmacology, toxicity and activity of high-dose...
BACKGROUND: The aim of this study was to assess the pharmacology, toxicity and activity of high-dose...
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopat...
Ifosfamide is an alkylating antineoplastic prodrug used to treat many solid tumors. The metabolism o...
Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are character...
Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are character...
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aim...